LEADERSHIP

Jeffrey_Brewer_Bigfoot

 

JEFFREY BREWER

Chief Executive Officer

Jeffrey Brewer is founder and CEO of Bigfoot Biomedical. Since his son’s 2002 diagnosis of Type 1 Diabetes (T1D), Jeffrey has been a thought leader and influencer in the diabetes community, first as a philanthropist who funded and launched the Artificial Pancreas Project along with JDRF Intl., then as JDRF’s CEO where he forged partnerships with industry to drive medical device innovation in diabetes. Jeffrey spearheaded US regulatory reform and elevated JDRF’s strategic priorities to include healthcare policy, reimbursement, and technology access. Previous to his work in diabetes, Jeffrey was an active entrepreneur where he founded and led highly successful dot-com start-ups including CitySearch and Overture / GoTo.com.

“People with diabetes don’t want another feature on a pump. They want a different way of living.”
Bryan Mazlish

 

BRYAN MAZLISH

Co-Founder, Executive Board Director

Before founding Bigfoot, Bryan previously led a successful career in quantitative finance, first as management in one of the world’s largest securities trading institutions, and subsequently as an entrepreneur, where he founded and led a fully automated trading company. Since his son’s diagnosis with T1D in 2011, Bryan has focused his efforts in the diabetes technology space where he invented algorithms for predicting glucose values and automating insulin delivery. His wife and son, both of whom have T1D, have benefited over the past four years from the use of a proof-of-concept device that he created to automate their insulin delivery. This is the first real-world demonstration of successful use of adaptive insulin delivery algorithms in pediatric and adult settings over an extended period of time.

“For the four years that my family has used the first system I created, diabetes has been so much easier to manage that it's like a different disease."
Ian_Hanson

 

IAN HANSON

Chief Operating Officer

Ian has a track record of over 20 years in device development, with a particular focus on drug delivery systems. In his most recent role as Senior Vice President and Chief Operating Officer at Unilife Corporation, Ian successfully spearheaded the development and scale-up of their wearable injector platform and advanced drug delivery systems. Prior to joining Unilife, Ian held senior leadership positions at Medtronic Diabetes, including leading the insulin pump R&D team. Over a span of more than a decade, Ian was responsible for the development and commercialization of innovative insulin delivery platforms and diabetes management systems. Ian joined Bigfoot in 2018 as the Chief Technology Officer and then the Chief Operating Officer in 2020. With extensive experience in regulated technologies, Ian is a highly skilled executive who excels in navigating complexities and driving success in commercializing medical technology. His strategic leadership, proven track record in managing R&D and business development, and expertise have positioned him well to continue leading Bigfoot through commercialization and scale-up.

Jim-Malone

 

JIM MALONE, MD

Chief Medical Officer

Dr. Malone is a diabetologist with 12 years of experience in clinical practice and more than 20 years of experience in clinical research at Eli Lilly & Company, where he developed diabetes products and delivery devices. At Bigfoot Biomedical, he leads the clinical and medical affairs teams and plays an integral role in shaping the company’s holistic approach to managing diabetes care to lessen the burden for both patients and health care professionals. Dr. Malone has been a long-time volunteer for JDRF, where he recently completed a 10-year term on the Indiana Chapter of the Board of Directors, including a term as President. He has also been active in the American Diabetes Association, where he served as President of the Indiana Affiliate, and volunteered as medical co-director at the ADA diabetes camp for 25 years.

Screenshot_20230221_115234_353x480

 

MATT RAINVILLE

Chief Commercial Officer

Matt is a commercial executive in the pharmaceutical and medical technology industry with more than two decades of leadership experience. He has extensive experience in sales, operations, and marketing strategies in the global diabetes market. Matt previously served as Insulet Corporation’s vice president and general manager of global Type 2 diabetes markets, where he led the company’s Omnipod Type 2 franchise after successfully spearheading the effort to drive pharmacy channel access for Omnipod DASH. Prior to Insulet, Matt spent 13 years with Eli Lilly and Company, where he held integral leadership roles in sales, training and development, marketing, operations, and market access – contributing to the successful launch of nine diabetes products globally. He has a BS in Marketing from the University of Connecticut and completed the HBX Core Program through Harvard Business School.

Clemente Family-148-Edit

 

MATTHEW JAMES CLEMENTE

SVP, Product Development & Delivery

Matthew has been a senior executive and CTO at Eli Lilly and Novo Nordisk, commercializing a myriad of connected medical devices, digital therapeutics and combination products. Having led the device and delivery R&D organizations at both Fortune 100 pharmaceutical companies he has world leading expertise in the commercialization of medical devices. In his roles at Johnson & Johnson and Unilife he has led successful startups from early concept through launch. He has a MBA from Villanova in Finance and a Bachelor of Biomedical Engineering from the University of Miami.

Kate_Lee-1

 

KATE LEE

SVP, Regulatory & Quality

Kate has served as Bigfoot's head of Regulatory Affairs and Quality Assurance since November 2015 and was instrumental in working on the clearance and subsequent launch of the Bigfoot Unity System. She brings more than 25 years of regulatory, quality and development experience in the medical device industry. Prior to joining Bigfoot, Kate provided regulatory and quality consulting to companies in the cardiovascular and diabetes spaces. Previously, Kate held a variety of leadership roles in regulatory and quality, where she had responsibility for establishing regulatory and compliance strategy in the US and beyond. Kate spent the first part of her career in R&D, developing and later leading teams in the development of innovative devices in the cardiovascular, vascular and gastroenterology specialties. Kate earned a Master’s degree in Smart Product Design from Stanford and a Bachelor’s degree in Mechanical Engineering from Harvard.

Geoff Shipsides

GEOFF SHIPSIDES

General Counsel

Geoff has served as Bigfoot's General Counsel since March 2019 and as Bigfoot’s Corporate Secretary since February 2023. Geoff is responsible for building Bigfoot’s legal structure and compliance framework, as well as advising on strategic transactions. From 2015 to 2019, he served as Bigfoot's Vice President, Intellectual Property, helping Bigfoot to develop a strong patent portfolio. Prior to joining Bigfoot, Geoff was a Principal at Fish & Richardson PC, where he focused on advising innovative medical device and consumer product companies.  Geoff earned a Bachelor of Science in Chemical Engineering from the University of Florida and his Juris Doctorate from Georgetown University Law Center. Prior to law school, Geoff worked as a Patent Examiner for the United States Patent and Trademark Office.

Lynn-Butler

 

LYNN BUTLER

VP, Human Resources

Lynn brings over 20 years of human resource and high volume recruiting experience building emerging growth technology companies throughout Silicon Valley. Lynn has held executive roles with a keen focus on high-quality rapid growth by aligning recruiting, compensation, benefit, and organizational strategies to achieve these aggressive growth plans with such companies as Netscape, Calico Commerce, and Sybase. Lynn also brings several years as an executive search consultant with DHR International where she led several leadership searches in the technology, nonprofit and educational sectors. Lynn’s daughter was diagnosed with T1D when she was 11 years old.